A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA: DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of stearidonic acid (SDA) and alpha-linolenic acid (ALA). The application further teaches methods of administering such combinations, and is directed towards unit dosages of such combinations for the reduction of apolipoprotein-B levels.Linvention concerne une composition et une méthode de traitement faisant intervenir une combinaison de statines (ou inhibiteurs de la HMG-CoA réductase), une classe de médicament utilisée pour abaisser les niveaux de cholestérol par inhibition de lenzyme HMG-CoA réductase, avec des mélanges dune formulation dacides gras oméga-3 contenant environ 90 % en poids ou plus dacides gras oméga-3 comprenant une combinaison dacide eicosapentaénoïque (EPA), dacide docosapentaénoïque (DPA) et dacide docosahexaénoïque (DHA) selon un rapport de poids EPA: DHA compris entre 5,7 et 6,3 la somme dEPA, de DHA et de DPA représentant environ 82 % en poids de la formulation totale et environ 92 % de la teneur totale en acides gras oméga-3 de la composition. LEPA et le DHA représentent environ 80 % de la formulation totale et environ 89 % d
